Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: A concrete example

BMC Infectious Diseases

Volumn 9, Issue , 2009, Pages

  Beran, Jiří ^a,b   Wertzova, Veronika ^a   Honegr, Karel ^b   Kaliskova, Eva ^d   Havlickova, Martina ^c   Havlik, Jiří ^a   Jirincova, Helena ^c   Van Belle, Pascale ^e   Jain, Varsha ^f   Innis, Bruce ^f   Devaster, Jeanne Marie ^e  

^a Vaccination and Travel Medicine Centre   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^c NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

^d GLAXOSMITHKLINE   (United Kingdom)

^e GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^f GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; PLACEBO; INACTIVATED VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; VIRUS ANTIBODY;

ADULT; ARTHRALGIA; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COUGHING; CZECH REPUBLIC; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FATIGUE; FEVER; HUMAN; IMMUNE RESPONSE; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MYALGIA; RANDOMIZED CONTROLLED TRIAL; SEASONAL VARIATION; SHIVERING; SORE THROAT; VIRUS CULTURE; VIRUS IDENTIFICATION; VIRUS ISOLATION; ADOLESCENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; IMMUNOLOGY; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; MALE;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CZECH REPUBLIC; DOUBLE-BLIND METHOD; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 60549097050     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-9-2     Document Type: Article

References (40)

1. World Health Organization (WHO): Influenza vaccines Wkly Epidemiol Rec 2005, 80:279-287. 16171031
2. Advisory Committee on immunization Practices (ACIP): Recommendations of the Advisory Committee on immunization Practices (ACIP) Prevention and control of influenza. Morbidity and Mortality Weekly Report 2008 57 RR-7
3. Demicheli V Rivetti D Deeks JJ Jefferson TO: Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2004 3 CD001269 15266445
4. Rose GW Cooper CL: Fluarix™, inactivated split-virus influenza vaccine. Expert Opin Biol Ther 2006, 6:301-310. 10.1517/14712598.6.3.301 16503738
5. Lin YP Gregory V Bennett M Hay A: Recent changes among human influenza viruses. Virus Res 2004, 103:47-52. 10.1016/j.virusres.2004.02.011 15163487
6. Kanegae Y Sugita S Endo A Ishida M Senya S Osako K Nerome K Oya A: Evolutionary pattern of the hemagglutinin gene of influenza B viruses isolated in Japan: Cocirculating lineages in the same epidemic season. J Virol 1990, 64:2860-2865. 249468 2335820
7. Rota PA Wallis TR Harmon MW Rota JS Kendal AP Nerome K: Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology 1990, 175:59-68. 10.1016/0042-6822(90)90186-U 2309452
8. Rota PA Hemphill ML Whistler T Regnery HL Kendal AP: Antigenic and genetic characterization of the hemagglutinin of recent cocirculating strains of influenza B virus. J Gen Virol 1992, 73:2737-2742. 10.1099/ 0022-1317-73-10-2737 1402807
9. Muñoz ET Deem MW: Epitope analysis for influenza vaccine design. Vaccine 2005, 23:1144-1148. 10.1016/j.vaccine.2004.08.028 15629357
10. Ferro VA: Improved design of the annual influenza vaccine using epitope analysis. Expert Review of Vaccines 2005, 4:157-161. 10.1586/ 14760584.4.2.157
11. World health organization (WHO): Recommendations for influenza vaccines http://www.who.int/csr/disease/influenza/vaccinerecommendations/en/ index.html
12. Langley JM Faughnan ME: Prevention of influenza in the general population. CMA J 2004, 171:1213-22. 15534315 524953
13. Skowronski DM Masaro C Kwindt TL Makb A Petric M Li Y Sebastian R Chonga M Tame T De Serres G: Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: Results from the 2005-2006 season of dual A and B vaccine mismatch in Canada. Vaccine 2007, 25:2842-2851. 10.1016/j.vaccine.2006.10.002 17081662
14. Hehme NW Künzel W Petschke F Türk G Raderecht C van Hoecke C Sänger R: Ten years of experience with the trivalent split-influenza vaccine, Fluarix™. Clin Drug Invest 2002, 22:751-769. 10.2165/00044011-200222110-00004
15. Treanor JJ Campbell JD Brady RC Keitel WA Drame M Jain VK Innis BL: Rapid licensure of a new, inactivated influenza vaccine in the United States. Human Vaccine 2005, 1:239-244. 17012883
16. Jefferson T: InflPenza vaccination: policy versus evidence. BMJ 2006, 333:912-915. 1626345 17068038 10.1136/bmj.38995.531701.80
17. Centers for Disease Control and Prevention (CDC): Overview of influenza surveillance in the United States http://www.cdc.gov/flu/weekly/ fluactivity.htm
18. Harmon MW: Influenza Viruses Laboratory Diagnosis of Viral Infections. Marcel Dekker, NY, USA Lennette EH 2 1992:515-534.
19. Manuguerra JC Hannoun C: Influenza and Other Respiratory Diseases Surveillance and Laboratory Diagnosis. Inst Pasteur Coll Lab Refer Exper 1999:186-189.
20. Waris M Ziegler T Kivivirta M Ruuskanen O: Rapid detection of respiratory syncytial virus and influenza A virus in cell cultures by immunoperoxidase staining with monoclonal antibodies. J Clin Microbiol 1990, 28:1159-1162. 267896 2199488
21. GreenwoodM Yule GU: The statistics of anti-typhoid and anti-cholera inoculations, and the interpretation of such statistics in general. Proc R Soc Med 1915, 8 (part 2):113-94.
22. European Committee for Medicinal Products for Human Use: Note for guidance on harmonization of requirements for influenza vaccines, March 1997 (CPMP/BWP/214/96) European Agency for the Evaluation of Medicinal Products
23. US Food and Drug Administration, Center for Biologics Evaluation and Research Guidance for Industry Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines 2007
24. Jefferson T Rivetti D Di C Pietrantonj C Rivetti A Demicheli V: Vaccines for Preventing Influenza in Healthy Adults. Cochrane Database Syst Rev 2007 2 CD001269 17443504
25. Ohmit SE Victor JC Rotthoff JR Teich ER Truscon RK Baum LL Rangarajan B Newton DW Boulton ML Monto AS: Prevention of Antigenically Drifted Influenza by Inactivated and Live Attenuated Vaccines Prevention of Antigenically Drifted Influenza by Inactivated and Live Attenuated Vaccines. New Eng J Med 2006, 355:2513-2522. 2614682 17167134 10.1056/ NEJMoa061850
26. Ohmit SE Victor JC Teich ER Truscon RK Rotthoff JR Newton DW Campbell SA Boulton ML Monto AS: Prevention of symptomatic seasonal infuenza in 2005 ± 2006 by inactivated and live attenuated vaccines. J Infect Dis 2008, 198(3):312-317. 2613648 18522501 10.1086/589885
27. Hoberman A Greenberg DP Paradise JL Rockette HE Lave JR Keraney DH Colborn DK Kurs-Lasky M Harslsm MA Byers CJ Zoffel LM Fabian IA Bernard BS Kerr JD: Effectiveness of an inactivated influenza vaccine in preventing accute otitis media in young children: A randomized controlled trial. JAMA 2003, 290(12):1608-1616. 10.1001/jama.290.12.1608 14506120
28. Meijer A Meerhoff TJ Meuwissen LE Velden van der J Paget WJ: Epidemiological and virological assessment of influenza activity in Europe during winter 2005-2006. Euro Surveill 2007, 12(9):E11-2. 17991413
29. European Influenza Surveillance Scheme Weekly total ILI morbidity per 100000 population The Czech Republic. EISS Weekly Electronic Bulletin 2006 2006 157 http://www.eiss.org/cgi-files/figures2002.cgi?year= 2006&week=16®ion=Czech+Republic&type=c (Accessed 09 January 2009).
30. European Influenza Surveillance Scheme Weekly total acute respiratory infections morbidity per 100000 population The Czech Republic. EISS Weekly Electronic Bulletin 2006 2006 157 http://www.eiss.org/cgi-files/ figures2002.cgi?year=2006&week=16®ion=Czech+Republic&type= c1
31. McCullers JA Saito T Iverson AR: Multiple Genotypes of Influenza B Virus Circulated between 1979 and 2003. J Virol 2004, 78:12817-12828. 525012 15542634 10.1128/JVI.78.23.12817-12828.2004
32. Aguilera JF Paget WJ Mosnier A Heijnen ML Uphoff H Velden van der J Vega T Watson JM: Heterogenous case definitions used for the surveillance of influenza in Europe. Eur J Epidemiol 2003, 18:751-754. 10.1023/ A:1025337616327 12974549
33. Hannoun C: Case definition for influenza surveillance. Eur J Epidemiol 2003, 18:737-738. 10.1023/A:1025300118935 12974545
34. Nichol KL: Heterogeneity of influenza case definitions and implications for interpreting and comparing study results. Vaccine 2006, 24:6726-6728. 10.1016/j.vaccine.2006.05.064 16879901
35. Zambon M Hays J Webster A Newman R Keene O: Diagnosis of influenza in the community-Relationship of clinical diagnosis to confirmed virological, serological, or molecular detection of influenza. Arch Intern Med 2001, 161:2116-2122. 10.1001/archinte.161.17.2116 11570941
36. Gooskens J Swaan CM Claas ECJ Kroes ACM: Rapid molecular detection of influenza outbreaks in nursing homes. J Clin Virol 2008, 41:7-12. 10.1016/j.jcv.2007.10.023 18065263
37. World Health Organization (WHO) Recommended composition of influenza virus vaccines for use in the 2006-2007 influenza season 2007 http://www.who.int/entity/csr/disease/influenza/2007northreport.pdf
38. Barr IG Komadina N Durrant C Sjogren H Hurt AC Shaw RP: Circulation and antigenic drift in human influenza B viruses in SE Asia and Oceania since 2000. Commun Dis Intell 2006, 30:350-357. 17120489
39. Levandowski RA Regnery HL Staton E Burgess BG Williams MS Groothuis JR: Antibody responses to influenza B viruses in immunologically unprimed children. Pediatrics 1991, 88:1031-1036. 1945607
40. Heckler R Baillot A Engelmann H Neumeier E Windorfer A: Cross-protection against homologous drift variants of Influenza A and B after vaccination with split vaccine. Intervirology 2007, 50:58-62. 10.1159/000096314 17164559